Long-Term Outcome of Otherwise Healthy Individuals with Incidentally Discovered Borderline Thrombocytopenia
Open Access
- 17 January 2006
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 3 (3) , e24
- https://doi.org/10.1371/journal.pmed.0030024
Abstract
The long-term outcome of individuals with mild degrees of thrombocytopenia is unknown. In a prospective study conducted between August 1992 and December 2002, 260 apparently healthy individuals with incidentally discovered platelet counts between 100 × 109/l and 150 × 109/l were monitored for 6 mo to determine whether their condition persisted. The monitoring period was completed in 217 cases, of whom 191 (88%) maintained stable platelet counts. These 191 individuals were included in a long-term follow-up study to gain knowledge of their natural history. With a median time of observation of 64 mo, the thrombocytopenia resolved spontaneously or persisted with no other disorders becoming apparent in 64% of cases. The most frequent event during the study period was the subsequent development of an autoimmune disease. The 10-y probability of developing idiopathic thrombocytopenic purpura (ITP), as defined by platelet counts persistently below 100 × 109/l, was 6.9% (95% confidence interval [CI]: 4.0%–12.0%). The 10-y probability of developing autoimmune disorders other than ITP was 12.0% (95% CI: 6.9%–20.8%). Most of the cases (85%) of autoimmune disease occurred in women. Healthy individuals with a sustained platelet count between 100 × 109/l and 150 × 109/l have a 10-y probability of developing autoimmune disorders of 12%. Further investigation is required to establish whether this risk is higher than in the general population and whether an intensive follow-up results in an improvement of prognosis.Keywords
This publication has 25 references indexed in Scilit:
- A note on competing risks in survival data analysisBritish Journal of Cancer, 2004
- Management of Immune Thrombocytopenic Purpura in AdultsMayo Clinic Proceedings, 2004
- The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosusArthritis & Rheumatism, 2004
- Effects of biological variations on platelet count in healthy subjects in ChinaThrombosis and Haemostasis, 2004
- Development of Autoantibodies before the Clinical Onset of Systemic Lupus ErythematosusNew England Journal of Medicine, 2003
- High-dose cyclophosphamide with autologous lymphocyte–depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopeniaBlood, 2003
- Further Evidence for a Strong Genetic Influence on the Development of Autoimmune Thyroid Disease: The California Twin StudyThyroid®, 2002
- Platelet count and parameters determined by the Bayer ADVIATM 120 in reference subjects and patientsClinical and Laboratory Haematology, 2001
- The determination of a reference range for new platelet parameters produced by the Bayer ADVIATM 120 full blood count analyserClinical and Laboratory Haematology, 2000
- Immune‐mediated platelet destruction and thrombocytopenia in patients with solid tumoursBritish Journal of Haematology, 1982